CN100345589C - Essential element nutritive preparation for intestine - Google Patents
Essential element nutritive preparation for intestine Download PDFInfo
- Publication number
- CN100345589C CN100345589C CNB2005101121822A CN200510112182A CN100345589C CN 100345589 C CN100345589 C CN 100345589C CN B2005101121822 A CNB2005101121822 A CN B2005101121822A CN 200510112182 A CN200510112182 A CN 200510112182A CN 100345589 C CN100345589 C CN 100345589C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- preparation
- oligomeric
- maltodextrin
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the technical field of a medical intestinal nutrition preparation, particularly to an intestinal essential element nutrition preparation for acute pancreatitis and clinical critical patients. The nutrition preparation of the present invention is the improvement of the existing intestinal nutrition preparation. The energy supply ratio of carbohydrate is reduced, maltodextrin is used as a main component, the ratio of medium-chain fatty acid is increased, the quantity of monounsaturated fatty acid is increased, the prebiotic components of a micro ecology preparation are added, and certain rare elements are added. The present invention avoids the occurrence of hyperglycemia and hyperlipemia, the intestinal barrier function is protected, and the present invention is favorable for the rehabilitation of patients.
Description
Technical field
The present invention relates to medical enteral nutrition preparation technical field, is a kind of essential element nutritive preparation for intestine that is used for acute pancreatitis and clinical critical patient.
Background technology
At present, hypermetabolism and pathological characteristic at acute pancreatitis (ASP), the method of taking during nutrition treatment in early days to give the enteral essential element nutritive through jejunum has caused people's attention, has the following advantages: because of supply with not stimulating pancreas secretion of nutrition through jejunum, just can not increase the weight of the state of an illness; Need not digestion can directly or near direct absorb; Satisfy patient's metabolism needs, effectively improve patient's nutriture, be beneficial to the recovery and the prognosis of disease; Simultaneously, also by the mechanical stimulus of Elental and the secretion of the system's hormone that stimulates digestion, and the recovery of acceleration gastrointestinal function and form, the protection intestinal barrier function, thus reduce the infection complication rate that the intestinal flora transposition causes.
The enteral nutrition preparation that used clinically jejunum is fed is the low fat elemental diet, and is composed as follows as the nutrient of the every 4.184MJ of EN preparation (1000kcal) of the U.S.: protein (free amino acid) 38.3g, fat (fatty acid and glycerol) 2.65g, carbohydrate (glucose and fructose) 205.6g, sodium 771mg, potassium 704mg, calcium 267mg, magnesium 117mg, chlorine 860mg, phosphorus 267mg, ferrum 3.3mg, zinc 3.7mg, manganese 940 μ g, copper 640 μ g, iodine 48 μ g, vitamin A 500 μ g, vitamin D 5 μ g, vitamin E 10mg, vitaminB10 .35mg, vitamin B2 0.4mg, vitamin B6 0.67mg, Catergen 3mg, vitamin PP 4.4mg, pantothenic acid 3.0mg, vitamin K 22 μ g, vitamin B12 1.7 μ g, folic acid 130mg, biotin 100mg, choline 25mg.Do not contain prebiotics.
Yet for patients with acute pancreatitis, body is digested and assimilated ability drop, particularly the fat constituent digestion power is reduced, if adopt low fat enteral nutrition prescription, carbohydrate then becomes the main source of energy, but at the high stress state of pancreatitis, there is insulin resistant, disposal ability to sugar also descends, so be prone to hyperglycemia, causes metabolism disorder; And under the high stress state of acute pancreatitis, it is impaired to be prone to intestinal barrier function, does not have specific protection material again.So existing enteral nutrition key element preparation can not adapt to the needs of patients with acute pancreatitis.So far do not see the enteral nutrition preparation that is exclusively used in patients with acute pancreatitis.
Summary of the invention
The invention provides a kind of essential element nutritive preparation for intestine of suitable patients with acute pancreatitis, it is a kind of all nutrition type preparation, can be used as the only source of nutrition of patients with acute pancreatitis, also can be used for the clinical critical patient under other high stress state, as patients such as serious burn, wound, infection multiple fractures, and patient such as hepatobiliary and pancreatic diseases, short bowel syndrome, digestive tube fistula, jejunum fistulation.
Nutritional preparation of the present invention is the improvement to existing essential element nutritive preparation for intestine, and one of improvement is the energy supply ratio that suitably reduces carbohydrate, to avoid SAP patient because of the impaired hyperglycemia that is caused of pancreatic function.Carbohydrate contains a small amount of disaccharidase and sucrose simultaneously based on maltodextrin, can avoid like this diarrhoea occurring because of osmotic pressure raises.Two of improvement is the ratios that increase medium-chain fatty acid, account for more than 20% of nutritional preparation gross energy, the ratio that accounts for fatty gross energy reaches more than 65%, because of medium-chain fatty acid does not rely on pancreatin can be directly through enteric epithelium access door Venous system, and do not cause pancreatic secretion, reach and not only improve patient's Nutrition and Metabolism but also do not increase the digestive system burden and do not increase the weight of the purpose of the state of an illness.Three of improvement is the amounts that increase monounsaturated fatty acid, accounts for 7% of nutritional preparation gross energy, and fat provides 22% of energy, and monounsaturated fatty acid has good effect for reducing blood fat, helps avoiding the concurrent hyperlipemia of SAP patient.Four of improvement is to add microbial ecological agent prebiotics (oligomeric carbohydrate); to promote the growth of enteral probiotic bacteria; help to make restoring balance of intestinal flora; can also improve the high-permeability of intestinal wall; improve the immunologic function of intestinal, the intestinal barrier function infringement has the certain protection effect during to acute pancreatitis.
Formulation components of the present invention and proportioning following [4186.8kJ (1000kal)]
Lact albumin hydrolysate 37～50g
Medium chain triglyceride 20～30g
Olive oil or Oleum Camelliae 11～17g
Phosphatidase 11～4g
Maltodextrin 110～140g
Glucose 0～15g
Vitamin A 450～850 μ g
Vitamin D 3～10 μ g
Vitamin E 5～150mg
Vitamin B1 0.3～50mg
Vitamin B2 0.4～2.2mg
Vitamin B6 0.5～2.5mg
Vitamin C 20～150mg
Vitamin PP 0.82～35.4mg
Pantothenic acid 3～12.5mg
Vitamin K 20～100 μ g
Vitamin B12 1.7～7.5 μ g
Folic acid 0.1～200mg
Biotin 5～150 μ g
Choline 25～250mg
Sodium 200～2200mg
Potassium 500～2000mg
Calcium 200～1000mg
Magnesium 100～350mg
Chlorine 500～1860mg
Phosphorus 200～1100mg
Ferrum 3～15mg
Zinc 3～11.5mg
Manganese 400～3500 μ g
Copper 500～2000 μ g
Iodine 25～150 μ g
Selenium 5～50 μ g
Fluorine 0.1～1.5mg
Chromium 5～50g
Molybdenum 15～60 μ g
Prebiotics 2～5g
Prebiotics is selected from a kind in oligomeric galactose, oligofructose, oligomeric xylose, oligomeric cottonseed sugar, the Oligomeric maltose; Add water to 1000 milliliters.
Preparation method is as follows:
By proportioning each component is added uniform mixing in the entry, sterilize behind the sealed packaging, keep in Dark Place.
Show that through zoopery preparation of the present invention can effectively improve the Nutrition and Metabolism situation under the morbid state, helps the recovery of disease; Compare with matched group, can protect the form and the function of intestinal mucosa specifically, reduce the incidence rate of bacterial translocation.
The specific embodiment
Now in conjunction with the embodiments, the present invention is described in detail.
Embodiment 1 preparation nutritional preparation EN-S of the present invention ()
The nutritional preparation component is as follows
Nutrient weight
Lact albumin hydrolysate 40g
Medium chain triglycerides 26.4g
Oleum Camelliae 11.1g
Phosphatidase 11 .4g
Maltodextrin 118g
Glucose 4.5g
Vitamin A 600 μ g
Vitamin D 3.5 μ g
Vitamin E 7.5mg
Vitamin B1 1mg
Vitamin B2 1.3mg
Vitamin B6 1.2mg
Vitamin C 45mg
Vitamin PP 9mg
Pantothenic acid 3.5mg
Vitamin K 50 μ g
Vitamin B12 2 μ g
Folic acid 100mg
Biotin 100 μ g
Choline 200mg
Sodium 750mg
Potassium 1250mg
Calcium 600mg
Magnesium 200mg
Chlorine 850mg
Phosphorus 470mg
Ferrum 10mg
Zinc 7.5mg
Manganese 500 μ g
Copper 650 μ g
Iodine 100 μ g
Selenium 5 μ g
Fluorine 1mg
Chromium 6 μ g
Molybdenum 15 μ g
Oligomeric galactose 3g
Embodiment 2 preparation EN-S nutritional preparations (two)
The nutritional preparation component is as follows
Nutrient weight
Lact albumin hydrolysate 37g
Medium chain triglycerides 22.9g
Olive oil 14g
Phosphatidase 12 g
Maltodextrin 120g
Glucose 5.5g
Vitamin A 650 μ g
Vitamin D 3 μ g
Vitamin E 14mg
Vitamin B1 1mg
Vitamin B2 1.3mg
Vitamin B6 1.2mg
Vitamin C 60mg
Vitamin PP 9mg
Pantothenic acid 3.5mg
Vitamin K 45 μ g
Vitamin B12 4 μ g
Folic acid 75mg
Biotin 120 μ g
Choline 180mg
Sodium 750mg
Potassium 1250mg
Calcium 650mg
Magnesium 220mg
Chlorine 825mg
Phosphorus 470mg
Ferrum 11mg
Zinc 8mg
Manganese 2100 μ g
Copper 1100 μ g
Iodine 80 μ g
Selenium 50 μ g
Fluorine 1.2mg
Chromium 25 μ g
Molybdenum 28 μ g
Oligomeric maltose 3.5g
Embodiment 3 preparation EN-S nutritional preparations (three)
The nutritional preparation component is as follows
Nutrient weight
Lact albumin hydrolysate 49g
Medium chain triglycerides 23.1g
Oleum Camelliae 12.6g
Phosphatidase 13 .2g
Maltodextrin 112g
Glucose 1.5g
Vitamin A 800 μ g
Vitamin D 4 μ g
Vitamin E 18mg
Vitamin B1 1.5mg
Vitamin B2 1.2mg
Vitamin B6 1.2mg
Vitamin C 100mg
Vitamin PP 8mg
Pantothenic acid 3mg
Vitamin K 45 μ g
Vitamin B12 4 μ g
Folic acid 75mg
Biotin 120 μ g
Choline 180mg
Sodium 750mg
Potassium 1250mg
Calcium 650mg
Magnesium 210mg
Chlorine 800mg
Phosphorus 470mg
Ferrum 11mg
Zinc 8.5mg
Manganese 2000 μ g
Copper 1000 μ g
Iodine 100 μ g
Selenium 20 μ g
Fluorine 1.1g
Chromium 10 μ g
Molybdenum 30 μ g
Oligofructose 2.8g
Preparation method
Above-mentioned each component is made into 1000 milliliters with distilled water, packing behind the mix homogeneously, the sealing sterilization is kept in Dark Place.
Zoopery
One, Animal Model of Acute Pancreatitis is set up
Laboratory animal cleaning level Sprague-Dawley (SD) male rat, in 6～7 ages in week, body weight 200 grams are provided by the The 2nd Army Medical College Experimental Animal Center.
Main agents: sodium taurocholate: Sigma company, purity 95%; Penthiobarbital: Shanghai Xinya Pharmaceutical Industry Co. Ltd.; Starch enzyme reagent kit: the institute of biological products is built up in Nanjing.
Test method:
1, animal grouping: after the SD rat was bought, adaptability fed for 1 week, was divided into SAP group (82) and matched group (25) at random.
2, the foundation of animal model: this experimental model is at reference literature " the downright bad type pancreatitis rats of acute hemorrhage model " (Wang Dansong, Jin Dayong etc. Shanghai laboratory animal science .2002,22 (1): on basis 23-26), concrete condition and requirement according to this experiment adjust slightly.The rat fasting was freely drunk water more than 12 hours before the experiment.Adopt 2.5% penthiobarbital intraperitoneal injection of anesthesia, dosage is the 0.1ml/100g body weight, unhairing, sterilization, shop aseptic towel.Advance abdomen through last median abdominal incision under the aseptic condition, softly pull out the harmonization of the stomach spleen, fully expose pancreas, mention spleen and tail of pancreas, begin the slowly even 3.8% sodium taurocholate 1ml of injection of multiple spot under the tunicle from tail of pancreas portion, whole pancreas is evenly swelled with syringe.Hyperemia, edema can appear in pancreatic tissue at short notice, and pancreatic tissue point-like or strip are hemorrhage under the then visible peplos that continues, and gently pancreas are resetted behind about 2min, and abdominal incision, i.e. cost experimental animal model are sewed up in layering.Matched group then cuts the abdominal cavity after anesthesia, gently turning over sews up the incision behind the pancreas gets final product.
3, serum amylase (AMS) detects: after rat SAP animal model is set up, respectively get 6 rats at 12 hours, 24 hours, 48 hours time points respectively, from ventral aorta blood sampling, the centrifugal 10min of 2000r/m, get 20 μ l upper serum, detect amylase activity.
4, pancreas pathological examination: put to death rat behind the arterial blood drawing immediately, get pancreas, use normal saline flushing, through fixing, dewater routinely, transparent, the waxdip embedding, section, dyeing, rinsing, wine soaks clearly, rinsing, colour developing, rinsing is redyed, it is transparent to dewater, and behind the resin encapsulation, observes the pathological change of pancreas under light microscopic.Carry out the pathological tissue scoring with double-blind method.
5, observe mortality rate: observe SAP rats death situation every day, continue 7 days, calculate mortality rate and 7 days general mortality rate of each time point.
Statistical analysis: The data SPSS10.0 software carries out statistical disposition, and the serum amylase activity difference adopts the t method of inspection relatively, and the pancreatic tissue pathological score adopts rank test.
The result
1, the serum amyloid enzyme assay the results are shown in Table 1
Table 1 SAP group and control rats serum amylase determination result (x ± s)
| Group | Model bring out the time (hour) | ||
| 12 hours | 24 hours | 48 hours | |
| Matched group (6) SAP model group (6) | 3160±251 5732±909 * | 2851±477 8157±535 * | 3292±504 7124±520 * |
* P＜0.01, compared with the control
Through the pancreas tunicle down evenly behind injection 3.8% sodium taurocholate, 12 hours serum amylases of SAP group raise by the visible rat of table 1, compare with matched group that there were significant differences (P＜0.01), peak after 24 hours, still keep very high level in 48 hours.
2, pancreatic tissue pathological change
The HE observation of dyeing, the pancreatic tissue acinus of control rats and islet tissue clear in structure, marshalling, cellular morphology is normal, no hemorrhagic necrosis; After the modeling 12 hours, the pancreatic tissue structure was slightly disorderly, and interstitial edema is obvious, a small amount of inflammatory cell infiltration, and a little acinous cell necrosis, but leaflet structure is still still clear; After the modeling 24 hours, the pancreatic tissue structure disturbance, interstitial fibers hamartoplasia, a small amount of inflammatory cell infiltration, leaflet structure is fuzzy, the necrosis of part acinous cell, the part acinus is the isolated island shape; After the modeling 48 hours, the pancreatic tissue structure disturbance, a matter hyperemia, hemorrhage, slight proliferation of fibrous tissue, the part inflammatory cell infiltration, leaflet structure is fuzzy, and acinous cell is most of downright bad, visible remaining acinus structure.
3, mortality rate is observed
Do not have deadly after the SAP modeling in 24 hours, the cumulative mortality of the 1st, 2,3,4,5,6 day and 7 days is respectively 0,9.4% (6/64), 25% (16/64), 37.5% (24/64), 42.2% (27/64), 46.9% (30/64) and 53.2% (33/64).Control rats does not have 1 example in 1 week dead.
From this laboratory observation to: evenly after the injection 3.8% sodium taurocholate 1ml, petechial hemorrhage and edema performance appear in pancreas very soon under the pancreas tunicle.The serum amyloid enzymatic activity all was significantly higher than matched group in 12 hours, 24 hours, 48 hours after modeling, peaked in 24 hours, after this began slightly to descend, but still was in high level.The pancreas pathological change increases the weight of gradually simultaneously, invades profit, hemorrhage to obvious necrosis from inflammatory, presents typical SAP pathological change.Prompting is when SAP, and along with pancreatic disorders is exacerbated to a certain degree, the release of pancreatin reduces on the contrary, and is similar with SAP patient's clinical manifestation.Observation to mortality rate finds that the mortality rate of 24 hours inner model animals is 0, the death toll height at the 3rd, 4 day, and the animal dead number reduced in the 5th, 6,7 day, and is more stable.
Illustrate that this experimental technique can successfully set up the SAP animal model, good reproducibility, the state of an illness is gradual development, is applicable to the nutrition treatment research of carrying out SAP.
Two, enteral nutrition preparation of the present invention is to SAP rat plasma aminogram and electrolytical influence
Laboratory animal: the same.
Main agents: Waters AccQ-Tag aminoacid dedicated kit (AccQ-Fluor
TMDerivative reagent 1, derivative reagent 2A, 2B; AccQ-Tag mobile phase A liquid, B liquid): Waters company, the U.S.; Aminoacid mixing standard specimen: Waters company, the U.S..
Test method
1, animal grouping: after the SD rat is bought, adaptability fed for 1 week, be divided into matched group (sewing up after only doing laparotomy), nutritional preparation EN-S of the present invention group (giving the EN-S preparation after making the SAP model) at random, common nutritional preparation EN organizes (giving common EN preparation after the modeling), 8 every group.
The EN-S preparation is the nutritional preparation of the present invention with embodiment 1 preparation: hydrolyzed whey Dan Bai is as protein source, fat is based on medium chain triglycerides, in, the ratio of long-chain fatty acid is 70: 30, long-chain contains soybean lecithin simultaneously based on monounsaturated fatty acid; Carbohydrate is based on maltodextrin; Contain the essential mineral of organism, vitamin, trace element etc., add oligomeric galactose.Every 100ml provides gross energy 100kcal, and carbohydrate, protein, fatty heat supply ratio are 49: 17: 34.
Common EN preparation compositing characteristic: free amino acid is a protein source; Fat accounts for 75% based on long-chain fatty acid.Every 100ml provides gross energy 100kcal, and carbohydrate, protein, fatty heat supply ratio are 82: 15: 3.See Table 2.
The trophic component characteristics of table 2 EN-S and common EN preparation relatively
| EN-S(100g) | Common EN (100g) | |
| Energy (kcal) protein source protein (g) protein supplies ratio of specific heat (%) non-protein energy: nitrogen carbohydrate (g) carbohydrate supplies ratio of specific heat (%) fat (g) medium chain fatty acid: LCFA fat is for ratio of specific heat (%) galactooligosaccharide | 432 100% hydrolyzed whey lists white 18.5 17 124.7: 1 53.5 49 17.5 70: 30 34 1.3 | 373 100% free amino acids 14.3 15 148.7: 1 76.7 82 0.99＜20: 80 30 |
2, animal model and nursing: set up animal model as stated above.Carry out gastroduodenal routinely and put pipe.Treat that the postoperative animal gave a small amount of normal saline flushing intestinal in clear-headed back 6 hours, begin intestinal instillation enteral nutrition preparation in the time of 12 hours, originally drip with 1.0ml/ hour the speed of dripping, and increase gradually, drip speed in the time of 36 hours to postoperative and reach 2.0ml/ hour, 50ml/d, and maintain this speed 7 days.
3, sacrifice of animal and collection of specimens: put to death animal at the 7th day, pluck eyeball and get blood, place anticoagulant tube, the centrifugal 15min of 2500r/m gets blood plasma, and-80 ℃ of preservations are to be analyzed.
4, blood plasma amino acid analysis:
(1) plasma sample pretreatment: get patient's blood plasma, put into " Ultrafree-MC " ultrafiltration cup of Millipore company, the centrifugal 10min of 8000r/m removes molecular weight greater than 10000 protein;
(2) analyte derivative is handled: get filtering serum 10 μ l and put into the sample introduction bottle, add the derivative reagent 2 that 20 μ l have prepared, the eddy mixer mixing adds derivative reagent 1 again, uses the eddy mixer mixing once more, places 1min under the room temperature, sample introduction;
(3) standard substance preparation: get the good aminoacid standard sample 10 μ l of dilution, concentration is 0.25 μ mol/L, puts into the sample introduction bottle, handles then with (2) step;
(4) chromatographic condition: mobile phase A, B liquid use behind the ultrasonic degas 10min before use; Adopt the AccQ-Tag chromatographic column specially for amino-acid, 37 ℃ of column temperatures, flow velocity 1.0ml/min, ultraviolet detection wavelength are 254nm, gradient is taken off the condition of washing and is seen Table 3.
Table 3 high performance liquid chromatogram carries out the gradient of amino acid analysis
| Time (min) | Flow velocity (ml/min) | Mobile phase A (%) | Mobile phase B (%) | Curve type |
| 0 17.0 24.0 32.0 34.0 35.0 37.0 38.0 45.0 | 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 | 100 91.1 72.0 67.0 67.0 0 0 100 100 | 0 9.0 28.0 33.0 33.0 100 100 0 0 | 6 6 6 6 6 6 6 6 6 |
5, blood plasma electrolyte analysis: adopt automatic clinical chemistry analyzer to detect.
The result
1, the result of blood plasma aminogram relatively sees Table 4
Table 4 is each group blood plasma aminogram result (μ mol/L) (x ± s) relatively
| Aminoacid | Matched group | The EN-S group | Common EN group |
| The total AA of Asp Ser Glu Gly His Arg Thr Ala Pro Cys Tyr Val Met Lys Ile Leu Phe BCAA | 173.6±56.1 408.1±156.8 693.7±220.2 517.8±201.1 563.8±296.2 539.7±264.7 503.7±176.9 628.4±157.6 247.3±66.8 150.2±79.1 91.3±49.0 221.2±92.41 142.2±43.3 444.0±97.1 149.9±65.0 194.6±74.4 116.7±45.2 594.2±86.2 5722.9±275.6 | 154.9±57.6 248.9±100.7 a 353.1±238.8 a 368.8±240.2 297.2±190.4 a 486.4±282.9 384.2±102.4 572.8±222.5 212.3±39.3 101.5±32.7 88.7±27.9 172.1±48.6 119.1±25.9 369.2.6±102.9 126.1±70.4 172.3±46.3 113.7±53.51 470.2±131.0 4279.0±463.1 a | 47.1±23.6 a，b 222.4±166.3 a 159.2±83.3 a，b 370.1±218.9 281.3±113.8 a 187.5±65.4 a，b 267.3±132.1 294.2±127.3 a，b 161.0±86.7 a 88.4±47.8 a 73.1±51.5 137.4±80.7 a 73.8±16.8 a，b 180.5±53.4 a，b 89.7±21.7 a 141.9±55.2 61.8±29.0 a，b 378.6±112.4 a 3473.2±927.9 a |
aP＜0.01 is with the matched group ratio;
bP＜0.05 is with EN-S group ratio
By table 4 as seen, the blood plasma amino acid levels of nutritional preparation EN-S group of the present invention is most not to have significant difference with matched group, and is significantly higher than the EN group.
2, the result of serum electrolyte relatively sees Table 5
Table 5 is each group blood plasma electrolyte result (x ± s) relatively
| Group | Electrolyte (mmol/L) | ||||||
| Na + | K + | Cl - | Ca 2+ | P 5+ | Mg 2+ | Fe 2+ | |
| Matched group EN-S organizes common EN group | 149.7±8.4 140.4±3.7 137.1±10.4 a | 26.7±0.5 26.8±6.1 24.4±3.9 | 90.3±7.3 86.9±3.3 76.7±27.3 | 0.22±0.01 0.21±0.02 0.21±0.02 | 3.5±0.1 3.1±0.7 3.4±0.7 | 0.15±0.03 0.13±0.02 0.12±0.03 a | 45.2±12.2 35.9±8.8 a， 21.6±3.9 a，b |
aP＜0.05 is with the matched group ratio;
bP＜0.05 is with EN-S group ratio
By table 5 as seen, the serum electrolyte of nutritional preparation EN-S group of the present invention is all approaching with matched group except that ferrous iron, and is better than the EN group generally.
Above-mentioned description of test nutritional preparation of the present invention (EN-S) can improve Nutrition and Metabolism better being better than common enteral nutrition preparation (EN) aspect the nitrogen balance of improving the SAP animal and the correction electrolyte disturbance.
Three, enteral nutrition preparation of the present invention is to the protective effect of SAP rat intestine barrier
Laboratory animal: the same.
Experimental technique:
1, animal grouping: animal is divided into matched group, EN-S group, EN group, and each experimental group is divided into 4 days nursing groups and 7 days nursing groups again.
2, animal model and nutrition treatment approach set up the same.
3, mesenteric lymph node regulating liver-QI antibacterial culturing: after the sacrifice of animal, under aseptic condition, get the mesenteric lymph node regulating liver-QI, weigh and be placed in the aseptic homogenizer, add the 0.5ml physiological saline solution, make homogenate, get respectively 100 μ l place increase 37 ℃ of bacterium culture plates cultivate increased bacterium in 24 hours after, carry out again that selectivity is cultivated and bacteriology's evaluation.
Statistical analysis: bacteria cultivation results adopts rank test (nonnormal distribution), and x is adopted in the check of bacterial translocation rate
2Check.
The result
Periphery internal organs intestinal flora dystopy the results are shown in Table 6
Table 6 is respectively organized bacterial translocation cultivation results (x ± s)
| Group (n=8) | MLN | Liver | |||
| Bacterial translocation rate (%) | Bacteria cultivation results (* 10 4CFU/g) | Bacterial translocation rate (%) | Bacteria cultivation results (* 10 4CFU/ml) | ||
| Contrast EN-S EN | A B E F G H | 12.5(1/8) 0 75.0(6/8) a 62.5(5/8) a 87.5(7/8) a 75.0(6/8) a | 0.00±0.00 0.00±0.00 1.11±1.20 a 0.79±0.56 a 6.51±7.63 a，b 6.22±1.28 a，b， | 0 0 75.0(6/8) a 75.0(6/8) a 87.5(7/8) a 75.0(6/8) a | 0 0 0.82±0.84 a， 0.56±0.42 a 2.86±1.99 a，b 07±1.43 a |
a: P＜0.01, with A or B group ratio;
b: P＜0.05, with E or F group ratio
Above-mentioned experimental result shows that the bacterial translocation rate of EN-S group and antibacterial culturing quantity reduce than the EN group, illustrate that nutritional preparation of the present invention compares with common enteral nutrition preparation, has the effect of protecting the intestinal barrier, preventing bacterial translocation.
In sum, nutritional preparation of the present invention is better than existing enteral nutrition preparation, is the essential element nutritive preparation for intestine that is suitable for clinical critical patient under patients with acute pancreatitis and other high stress state.
Claims (4)
1, a kind of essential element nutritive preparation for intestine, component and proportioning are as follows:
Lact albumin hydrolysate 37～50g
Medium chain triglyceride 20～30g
Olive oil or Oleum Camelliae 11～17g
Phosphatidase 11～4g
Maltodextrin 110～140g
Glucose 0～15g
Vitamin A 450～850 μ g
Vitamin D 3～10 μ g
Vitamin E 5～150mg
Vitamin B1 0.3～50mg
Vitamin B2 0.4～2.2mg
Vitamin B6 0.5～2.5mg
Vitamin C 20～150mg
Vitamin PP 0.82～35.4mg
Pantothenic acid 3～12.5mg
Vitamin K 20～100 μ g
Vitamin B12 1.7～7.5 μ g
Folic acid 0.1～200mg
Biotin 5～150 μ g
Choline 25～250mg
Sodium 200～2200mg
Potassium 500～2000mg
Calcium 200～1000mg
Magnesium 100～350mg
Chlorine 500～1860mg
Phosphorus 200～1100mg
Ferrum 3～15mg
Zinc 3～11.5mg
Manganese 400～3500 μ g
Copper 500～2000 μ g
Iodine 25～150 μ g
Selenium 5～50 μ g
Fluorine 0.1～1.5mg
Chromium 5～50 μ g
Molybdenum 15～60 μ g
Prebiotics 2～5g
Prebiotics is selected from a kind of in oligomeric galactose, oligofructose, oligomeric xylose, oligomeric cottonseed sugar, the Oligomeric maltose; Add water to 1000 milliliters.
2, by the described nutritional preparation of claim 1, it is characterized in that proportioning is as follows:
Lact albumin hydrolysate 40g
Medium chain triglycerides 26.4g
Oleum Camelliae 11.1g
Phosphatidase 11 .4g
Maltodextrin 118g
Glucose 4.5g
Vitamin A 600 μ g
Vitamin D 3.5 μ g
Vitamin E 7.5mg
Vitamin B1 1mg
Vitamin B2 1.3mg
Vitamin B6 1.2mg
Vitamin C 45mg
Vitamin PP 9mg
Pantothenic acid 3.5mg
Vitamin K 50 μ g
Vitamin B12 2 μ g
Folic acid 100mg
Biotin 100 μ g
Choline 200mg
Sodium 750mg
Potassium 1250mg
Calcium 600mg
Magnesium 200mg
Chlorine 850mg
Phosphorus 470mg
Ferrum 10mg
Zinc 7.5mg
Manganese 500 μ g
Copper 650 μ g
Iodine 100 μ g
Selenium 5 μ g
Fluorine 1mg
Chromium 6 μ g
Molybdenum 15 μ g
Oligomeric galactose 3g.
3, by the described nutritional preparation of claim 1, it is characterized in that proportioning is as follows:
Lact albumin hydrolysate 37g
Medium chain triglycerides 22.9g
Olive oil 14g
Phosphatidase 12 g
Maltodextrin 120g
Glucose 5.5g
Vitamin A 650 μ g
Vitamin D 3 μ g
Vitamin E 14mg
Vitamin B1 1mg
Vitamin B2 1.3mg
Vitamin B6 1.2mg
Vitamin C 60mg
Vitamin PP 9mg
Pantothenic acid 3.5mg
Vitamin K 45 μ g
Vitamin B12 4 μ g
Folic acid 75mg
Biotin 120 μ g
Choline 180mg
Sodium 750mg
Potassium 1250mg
Calcium 650mg
Magnesium 220mg
Chlorine 800mg
Phosphorus 470mg
Ferrum 11mg
Zinc 8mg
Manganese 2100 μ g
Copper 1100 μ g
Iodine 80 μ g
Selenium 50 μ g
Fluorine 1.2mg
Chromium 25 μ g
Molybdenum 30 μ g
Oligomeric maltose 3.5g.
4, by the described nutritional preparation of claim 1, it is characterized in that proportioning is as follows:
Lact albumin hydrolysate 49g
Medium chain triglycerides 23.1g
Oleum Camelliae 12.6g
Phosphatidase 13 .2g
Maltodextrin 112g
Glucose 1.5g
Vitamin A 800 μ g
Vitamin D 4 μ g
Vitamin E 18mg
Vitamin B1 1.5mg
Vitamin B2 1.2mg
Vitamin B6 1.2mg
Vitamin C 100mg
Vitamin PP 8mg
Pantothenic acid 3mg
Vitamin K 45 μ g
Vitamin B12 4 μ g
Folic acid 75mg
Biotin 120 μ g
Choline 180mg
Sodium 750mg
Potassium 1250mg
Calcium 650mg
Magnesium 220mg
Chlorine 800mg
Phosphorus 470mg
Ferrum 11mg
Zinc 8.5mg
Manganese 2000 μ g
Copper 1000 μ g
Iodine 100 μ g
Selenium 20 μ g
Fluorine 1mg
Chromium 6 μ g
Molybdenum 15 μ g
Oligofructose 2.8g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101121822A CN100345589C (en) | 2005-12-29 | 2005-12-29 | Essential element nutritive preparation for intestine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101121822A CN100345589C (en) | 2005-12-29 | 2005-12-29 | Essential element nutritive preparation for intestine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1824293A CN1824293A (en) | 2006-08-30 |
| CN100345589C true CN100345589C (en) | 2007-10-31 |
Family
ID=36935237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101121822A Expired - Fee Related CN100345589C (en) | 2005-12-29 | 2005-12-29 | Essential element nutritive preparation for intestine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100345589C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102648749A (en) * | 2012-04-24 | 2012-08-29 | 广州金酮医疗科技有限公司 | Ketogenic nutritional powder |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2627197A4 (en) * | 2010-10-14 | 2017-05-24 | Asha Nutrition Sciences, Inc. | Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof |
| CN103431260B (en) * | 2013-08-31 | 2014-08-20 | 山东卫康生物医药科技有限公司 | Mixed-grain full-nutrition formulation food for patients with gastrointestinal tract malabsorption and pancreatitis |
| CN105455133A (en) * | 2015-12-08 | 2016-04-06 | 西安力邦临床营养股份有限公司 | Predigestion type total nutrient solution and preparation method thereof |
| CN106880035A (en) * | 2015-12-15 | 2017-06-23 | 范旻 | A kind of total enteral nutritious product of regulating intestinal canal flora imbalance and preparation method thereof |
| CN106072530A (en) * | 2016-06-18 | 2016-11-09 | 江苏阜丰生物科技有限公司 | A kind of full nutritional formulas of anti-protein allergies |
| CN107467641A (en) * | 2017-07-24 | 2017-12-15 | 哈尔滨工业大学 | A kind of type plant person's special nasal feeding nutrient combo on the one |
| CN112450442A (en) * | 2020-12-17 | 2021-03-09 | 温州市人民医院 | Enteral nutrition preparation for gastrointestinal adverse reactions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156738A (en) * | 1996-04-12 | 2000-12-05 | Bell; Stacey J. | Diabetic supplement bar |
| CN1620920A (en) * | 2004-12-31 | 2005-06-01 | 北京东方兴企食品工业技术有限公司 | Composite fungi amylose nutrient |
-
2005
- 2005-12-29 CN CNB2005101121822A patent/CN100345589C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156738A (en) * | 1996-04-12 | 2000-12-05 | Bell; Stacey J. | Diabetic supplement bar |
| CN1620920A (en) * | 2004-12-31 | 2005-06-01 | 北京东方兴企食品工业技术有限公司 | Composite fungi amylose nutrient |
Non-Patent Citations (1)
| Title |
|---|
| 酶法水解乳清蛋白过程的优化 刘利军 等，天津科技大学学报，第20卷第3期 2005 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102648749A (en) * | 2012-04-24 | 2012-08-29 | 广州金酮医疗科技有限公司 | Ketogenic nutritional powder |
| CN102648749B (en) * | 2012-04-24 | 2013-05-29 | 广州金酮医疗科技有限公司 | Ketogenic nutritional powder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1824293A (en) | 2006-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100345589C (en) | Essential element nutritive preparation for intestine | |
| CN1939532A (en) | Use of fungal immunomodulatory protein | |
| CN1867258A (en) | Stable liquid probiotic composition, preparation and applications thereof | |
| CN1920049A (en) | Small molecule bioactive peptide, preparation method, composition and application thereof | |
| CN1761686A (en) | Proteoglycan isolated from cartilaginous fish and process for producing the same | |
| CN1284134A (en) | Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system | |
| CN1313775A (en) | Methods and materials for the treatment of prostatic cercinoma | |
| CN1717184A (en) | Methods and compositions for providing glutamine | |
| CN1198639C (en) | Immune enhancing compositions | |
| CN1699419A (en) | Human blood high density lipoprotein, its manufacturing method and application | |
| CN1699417A (en) | Human blood high density lipoprotein, its manufacturing method and application | |
| CN1212381C (en) | Fruit kernel oil extracted from plant fruit kernel, its extraction method, medicinal composite and application | |
| CN101045745A (en) | Scale preparation method of bursin and application of used as avian influema vaccine adjuvant | |
| CN100346804C (en) | Medicine for treating chronic gastropathy and its preparation method | |
| CN1947727A (en) | Anti-echidnotoxin blood serum and its preparing method | |
| CN1566136A (en) | Pasqueflower notoginsenosides and extraction method, medicinal uses and pharmaceutical preparation thereof | |
| CN1879880A (en) | Use of immunological stimulant compound(ISCOMs)in fish immunity by oral administration and dipping bath method | |
| CN1511443A (en) | Method for cultivating Bailing mushroom and Disease prevention improver containing Bailing mushroom | |
| CN1063091C (en) | Functional milk for immunization | |
| CN1264522C (en) | Medicinal composition, its preparation method and its use | |
| CN1840179A (en) | Application of bovine lactoferricin in preparation of medicine for treating HP infected gastric disease | |
| CN1323688C (en) | Medicine composition for treating prostatosis and method for preparing the same | |
| CN1076966C (en) | Medicine for curing diabetes and nephrosis and delaying chronic renal failure | |
| CN1270773C (en) | Application of chitosan for preparing helicobacter pylorus vaccine adjuvant | |
| CN1216614C (en) | Medicinal composition for relaxing chronic renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071031 Termination date: 20100129 |